

List of Publications: PD Dr. med. Thomas Hermanns

1. Original Articles (peer reviewed)

Impact factors (IF) according to the latest Journal Citation Reports® Science Edition 2020

1. Brook GA, Houweling DA, Gieling RG, **Hermanns T**, Joosten EA, Bär DP, Gispen WH, Schmitt AB, Leprince P, Noth J, Nacimiento W (2000)
Attempted endogenous tissue repair following experimental spinal cord injury in the rat: involvement of cell adhesion molecules L1 and N-CAM?
Eur J Neurosci. 12(9): 3224-38
Impact Factor: 3.386
2. **Hermanns T**, Sulser T, Fatzer M, Baumgartner MK, Rey JM, Sigrist MW, Seifert HH (2009)
Laser fibre deterioration and loss of power output during photo-selective 80-W potassium-titanyl-phosphate laser vaporisation of the prostate.
Eur Urol. 55(3): 679-85
Impact factor: 20.096
3. Baumgartner MK, **Hermanns T**, Cohen A, Schmid DM, Seifert B, Sulser T, Strebel RT (2008)
Patient's knowledge about risk factors for erectile dysfunction is poor.
J Sex Med. 5(10): 2399-404
Impact factor: 3.802
4. Sørensen KD, Wild PJ, Mortezaei A, Adolf K, Tørring N, Heebøll S, Ulhøi BP, Ottosen P, Sulser T, **Hermanns T**, Moch H, Borre M, Ørntoft TF, Dyrskjødt L (2009)
Genetic and epigenetic SLC18A2 silencing in prostate cancer is an independent adverse predictor of biochemical recurrence after radical prostatectomy.
Clin Cancer Res. 15(4): 1400-10
Impact factor: 12.531
5. **Hermanns T**, Sauermann P, Rufibach K, Frauenfelder T, Sulser T, Strebel RT (2009)
Is there a role for Tamsulosin in the treatment of distal ureteral stones of 7mm or less? Results of a randomised, double-blind, placebo-controlled trial.
Eur Urol. 56(3): 407-12
Impact factor: 20.096
6. Wild PJ, Fuchs T, Stoehr R, Zimmermann D, Frigerio S, Padberg B, Steiner I, Zwarthoff EC, Burger M, Denzinger S, Hofstaedter F, Kristiansen G, **Hermanns T**, Seifert HH, Provenzano M, Sulser T, Roth V, Buhmann JM, Moch H, Hartmann A (2009)
Detection of urothelial bladder cancer cells in voided urine can be improved by a combination of cytology and standardized microsatellite analysis.
Cancer Epidemiol Biomarkers Prev. 18(6): 1798-806
Impact factor: 4.254

7. Tischler V, Fritzsche R, Wild PJ, Stefan C, Seifert HH, Riener MO, **Hermanns T**, Gerhardt J, Schraml P, Jung K, Moch H, Soltermann A, Kristiansen G (2010)
Periostin is up-regulated in high grade and high stage prostate cancer.
BMC Cancer. 10: 273-81
Impact factor: 3.288

8. Ikenberg K, Fritzsche FR, Zuerrer-Haerdi U, Hofmann I, **Hermanns T**, Seifert H, Müntener M, Provenzano M, Sulser T, Behnke S, Gerhardt J, Mortezaavi A, Wild P, Hofstädter F, Burger M, Moch H, Kristiansen G (2010)
Insulin-like growth factor II mRNA binding protein 3 (IMP3) is overexpressed in prostate cancer and correlates with higher Gleason scores.
BMC Cancer. 10: 341-6
Impact factor: 4.430

9. Mortezaavi A, **Hermanns T**, Seifert HH, Baumgartner MK, Provenzano M, Sulser T, Burger M, Hofstädter F, Krek W, Hartmann A, Moch H, Kristiansen G, Wild PJ (2011)
KPNA2 expression is an independent adverse predictor of biochemical recurrence after radical prostatectomy.
Clin Cancer Res. 17(5): 1111-21
Impact factor: 12.531

10. Gerhardt J, Steinbrech C, Büchi O, Behnke S, Bohnert A, Fritzsche FR, Wild PJ, Schraml P, **Hermanns T**, Müntener M, Kristiansen G (2011)
The androgen-regulated calcium-activated nucleotidase 1 is strongly overexpressed in prostate cancer and is tumorbiologically relevant in vitro.
Am J Pathol. 178(4): 1847-60
Impact factor: 4.307

11. **Hermanns T**, Strebel DD, Hefermehl LJ, Gross O, Mortezaavi A, Müller A, Eberli D, Müntener M, Michel MS, Meier AH, Sulser T, Seifert HH (2011)
Lithium triborate-laser vaporisation of the prostate using the 120W, high performance system laser: high performance all the way?
J Urol. 185(6): 2241-7
Impact factor: 7.450

12. Beer M, Montani M, Gerhardt J, Wild PJ, Hany T, **Hermanns T**, Müntener M, Kristiansen G (2012)
Profiling gastrin releasing peptide receptor in prostate tissues: clinical implications and molecular correlates.
Prostate. 72(3): 318-25
Impact factor: 4.014

13. Von Boehmer L, Keller L, Mortezaavi A, Provenzano M, Sais G, **Hermanns T**, Sulser T, Jungbluth AA, Old LJ, Kristiansen G, van den Broek M, Moch H, Knuth A, Wild PJ (2011)
MAGE-C2/CT10 protein expression is an independent predictor of recurrence in prostate cancer.

14. Gerhardt J, Montani M, Wild PJ, Beer M, Huber F, **Hermanns T**, Müntener M, Kristiansen G (2012)
FoxA1 promotes tumor progression in prostate cancer and represents a novel hallmark of castrate resistant prostate cancer.
Am J Pathol. 180(2): 848-61
Impact factor: 4.307
15. Beermann A, Ghanjati F, **Hermanns T**, Poyet C, Fischer PJ, Wernet P, Santourlidis S (2011)
Methods for Separate Isolation of Cell-Free DNA and Cellular DNA from Urine- Application of Methylation-Specific PCR on both DNA Fractions
The Open Biomarker J. 4: 15-17
Impact factor: n/a
16. Mortezaei A, **Hermanns T**, Seifert HH, Wild PJ, Schmid DM, Sulser T, Eberli D (2012)
Intrafascial dissection significantly increases positive surgical margin and biochemical recurrence rates after robotic assisted radical prostatectomy.
Urol Int. 26: 17-24
Impact factor: 2.089
17. Boysen G, Bausch-Fluck D, Thoma CR, Novicka AM, Stiehl DP, Cima IL, Luu V, von Teichman A, **Hermanns T**, Sulser T, Ingold-Heppner B, Fankhauser N, Wenger RH, Krek W, Schraml P, Wollscheid B, Moch H (2012)
Relative quantification of the renal carcinoma surfaceome reveals pVHL-dependent cell surface glycoproteins as clinical markers.
Neoplasia. 14(6): 535-46
Impact factor: 5.715
18. Montani M, **Hermanns T**, Müntener M, Wild P, Sulser T, Kristiansen G (2013)
Multidrug resistance protein 4 (MRP4) expression in prostate cancer is associated with androgen signalling and decreases with tumor progression.
Virchows Arch. 463(1): 437-46
Impact factor: 4.064
19. Kaufmann MR, Schraml P, **Hermanns T**, Wenger RH, Camenisch G (2013)
Onconeural antigen Cdr2 correlates with HIF prolyl-4-hydroxylase PHD1 and worse prognosis in renal cell carcinoma.
Exp Mol Pathol. 94(3): 453-457
Impact factor: 3.362
20. Mortezaei A, **Hermanns T**, Hefermehl LJ, Spahn D, Seifert B, Weber DR, Schmid DM, Sulser T, Eberli D (2013)
Continuous anti-platelet therapy in robotic-assisted laparoscopic radical prostatectomy.

J Laparoendosc Adv Surg Tech A. 23(6): 500-5

Impact factor: 1.878

21. Dannenmann SR, Thielicke J, Stöckli M, Matter C, von Boehmer L, Cecconi V, **Hermanns T**, Hefermehl L, Schraml PH, Moch H, Knuth A, van den Broek M (2013)
Tumor-associated macrophages subvert T-cell function and correlate with reduced survival in clear cell renal cell carcinoma.
Oncoimmunology. 2(3): e23562
Impact factor: 8.110
22. **Hermanns T**, Fankhauser CD, Hefermehl, LJ, Kranzbühler B, Wong LM, Capol JC, Zimmermann M, Sulser T, Müller A (2013)
Prospective evaluation of irrigation fluid absorption during pure transurethral bipolar plasma vaporisation of the prostate using expired breath ethanol measurements.
BJU Int. 112(5): 647-54
Impact factor: 5.588
23. Kranzbühler B, Wettstein MS, Fankhauser CD, Grossmann NC, Gross O, Poyet C, Largo R, Fischer B, Zimmermann M, Sulser T, Müller A, **Hermanns T** (2013)
Pure bipolar plasma vaporization of the Prostate: The Zürich experience.
J Endourol. 27(10): 1261-6
Impact factor: 2.942
24. Hefermehl LJ, Largo R, **Hermanns T**, Poyet C, Sulser T, Eberli D (2013)
Lateral temperature spread of monopolar, bipolar and ultrasonic instruments for robotic assisted laparoscopic surgery.
BJU Int. 114(2): 245-52
Impact factor: 5.588
25. **Hermanns T**, Gross O, Kranzbühler B, Hefermehl LJ, Poyet C, Fankhauser CD, Müller A, Yap SA, Michel MS, Eberli A, Müntener M, Zimmermann M, Sulser T, Seifert HH (2013)
Ablative efficiency of 532 nm laser vaporization compared to transurethral resection of the prostate: Results from a prospective three-dimensional ultrasound volumetry study.
World J Urol. 32(5): 1267-74
Impact factor: 4.226
26. Poyet C, Jentsch B, **Hermanns T**, Schweckendieck D, Seifert HH, Schmidtpeter M, Sulser T, Moch H, Wild PJ, Kristiansen G (2014)
Expression of histone deacetylases 1, 2 and 3 in urothelial bladder cancer.
BMC Clin Pathol. 14(1): 10
Impact factor: n/a
27. Dannenmann SR, **Hermanns T**, Bransi A, Matter C, von Boehmer L, Stevanovic S, Schraml PH, Moch H, Knuth A, van den Broek M (2013)

Spontaneous peripheral T cell responses towards the tumor-associated antigen Cyclin D1 in patients with clear cell renal cell carcinoma.

Cancer Immunol Res. 1(5): 288-95

Impact factor: 11.151

28. Templeton AJ, Ace O, McNamara MG, Al-Mubarak M, Vera-Badillo FE, **Hermanns T**, Šeruga B, Ocaña A, Tannock IF, Amir E (2014)

Prognostic Role of Platelet to Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis.

Cancer Epidemiol Biomarkers Prev. 23(7): 1204-12

Impact factor: 4.254

29. **Hermanns T**, Bhindi B, Wei Y, Yu J, Noon AP, Richard PO, Bhatt JR, Almatar A, Jewett MAS, Fleshner NE, Zlotta AR, Templeton AJ, Kulkarni GS (2014)

Pretreatment neutrophil-to-lymphocyte ratio as predictor of adverse outcomes in patients undergoing radical cystectomy for urothelial carcinoma of the bladder.

Br J Cancer. 111(3): 444-51

Impact factor: 7.640

30. **Hermanns T**, Grossmann NC, Wettstein MS, Fankhauser CD, Capol JC, Poyet C, Hefermehl LJ, Zimmermann M, Sulser T, Müller A (2015)

Absorption of irrigation fluid occurs frequently during high-power 523nm laser vaporization of the prostate.

J Urol. 193(1): 211-6

Impact factor: 7.450

31. Ghanjati F, Beermann A, **Hermanns T**, Poyet C, Araúzo-Bravo MJ, Seifert HH, Schmidpeter M, Goering W, Sorg R, Wernet P, Santourlidis S (2014)

Unreserved application of epigenetic methods to define differences of DNA methylation between urinary cellular and cell-free DNA.

Cancer Biomark. 14(5): 295-302

Impact factor: 4.388

32. Liu Y, Noon AP, Cabeza EA, Shen J, Kucic , Ilczynski C, Ni R, Sukhu B, Chan K, Barbosa-Morais NL, **Hermanns T**, Blencowe BJ, Azad A, van der Kwast TH, Catto JWF, Zlotta AR, Wrana JL (2014)

Next generation RNA sequencing of archival formalin fixed paraffin embedded urothelial bladder cancer.

Eur Urol. 66(6): 982-6

Impact factor: 20.096

33. Richard PO, Abramsky H, Bhatt JR, **Hermanns T**, Hersey KM, Chadwick K, Habeeba B, Fleshner NE (2015)

Impact of energy drinks on androgen deprivation induced fatigue: Results of a pilot study

J Caffeine Res. 5(1): 50-4

Impact factor: n/a

34. Ruf M, Fieger C, Hartmann A, **Hermanns T**, Poyet C, van den Broek M, Sulser T, Moch H, Schraml P (2015)
CD70 is upregulated via the pVHL-HIF α axis and triggers the release of the soluble form of its receptor CD27 from tumour infiltrating lymphocytes in renal cell carcinoma.
Clin Cancer Res. 21(4): 889-98
Impact factor: 12.531
35. Richard PO, Bhatt JR, **Hermanns T**, Juvet T, Manickavachagam K, Evans AJ, Kachura JR, Jewett MAS, Finelli A (2015)
The Outcome of Renal Tumor Biopsies for Small Renal Masses: A Single-Center 13-year Experience.
Eur Urol. 68(6): 1007-13
Impact factor: 20.096
36. Nayan M, Bhindi B, Yu JL, **Hermanns T**, Hamilton RJ, Finelli A, Jewett MAS, Zlotta AR, Fleshner NE, Kulkarni GS (2015)
The impact of metformin on cancer-specific survival outcomes in diabetic patients undergoing radical cystectomy for urothelial carcinoma of the bladder.
Urol Oncol – Semin Ori. 33(9): 386 e7-13
Impact factor: 3.498
37. Benoit T, Keller E, Wolfsgruber P, **Hermanns T**, Günthart M, Banzola I, Sulser T, Provenzano M, Poyet C (2015)
High VEGF-D and low MMP-2 serum levels predict nodal positive disease in invasive bladder cancer.
Med Sci Monit. 21: 2266-74
Impact factor: 2.649
38. Poyet C, Buser L, Roudnicky F, Detmar M, **Hermanns T**, Mannhard D, Höhn A, Sulser T, Moch H, Wild PJ (2015)
Connexin 43 expression predicts poor progression-free survival in patients with non-muscle invasive urothelial bladder cancer.
J Clin Pathol. 68(10): 819-24
Impact factor: 3.411
39. Poyet C, Nieboer D, Bhindi B, Kulkarni GS, Wiederkehr C, Largo R, Wild PJ, Sulser T, **Hermanns T** (2016)
Prostate cancer risk prediction using the updated ERSPC and PCPT risk calculators: Independent validation and comparison in a contemporary European cohort.
BJU Int. 117(3): 401-8
Impact factor: 5.588
40. Wettstein MS, Buser L, **Hermanns T**, Roudnicky F, Eberli D, Baumeister P, Sulser T, Wild P, Poyet C (2015)
CD73 predicts favourable prognosis in patients with non-muscle invasive urothelial bladder cancer.
Dis Markers. 2015: 785461

Impact factor: 3.434

41. Bhindi B, **Hermanns T***, Wei Y, Yu J, Templeton AJ, Richard PO, Wettstein MS, Shirdhar SS, Jewett MAS, Fleshner NE, Zlotta AR, Kulkarni GS (2016)

How to best use the complete blood count to predict oncologic outcomes following radical cystectomy for bladder cancer.

Br J Cancer. 114(2): 207-12

Impact factor: 7.640

42. Mortezaei A, Sulser T, Robbiani J, Drescher E, Disteldorf D, Eberli D, Poyet C, Baumgartner MK, Seifert HH, **Hermanns T** (2016)

Long-term oncological outcome of an initial series of laparoscopic radical prostatectomy for clinically localized prostate cancer after a median follow-up of 10 years.

Clin Genitourin Cancer. 14(4):290-7

Impact factor: 2.872

43. Poyet C, **Hermanns T**, Zhong Q, Eberli D, Burger M, Hofstaedter F, Hartmann A, Stöhr R, Zwarthoff EC, Sulser T, Wild PJ (2015)

Positive FGFR3 immunoreactivity defines low-grade urothelial bladder cancer.

Oncol Lett. 10(5): 2753-60

Impact factor: 2.967

44. Wettstein MS, Poyet C, Grossmann NC, Fankhauser CD, Keller XE, Kozomara M, Meyer S, Sulser T, Müller A, **Hermanns T** (2016)

Absorption of irrigation fluid during XPS™ GreenLight laser vaporization of the prostate: results from a prospective breath ethanol monitoring study.

World J Urol. Epub. ahead of print

Impact factor: 4.226

45. Santourlidis S, Ghanjati F, Beermann A, **Hermanns T**, Poyet C (2016)

IDLN-MSP - Idioloical normalization of real-time methylation-specific PCR for genetic imbalanced DNA specimens.

BioTechniques. 60(2): 84-7

Impact factor: 1.993

46. Nayan M, Bhindi B, Yu JL, Mamdani M, Fleshner NE, **Hermanns T**, Chung P, Milosevic M, Bristow R, Warde P, Hamilton RJ, Finelli A, Jewett MAS, Zlotta AR, Shridhar SS, Kulkarni GS (2016)

The initiation of a multidisciplinary bladder cancer clinic and the uptake of neoadjuvant chemotherapy: A time-series analysis.

Can Urol Assoc J. 10(1-2): 25-30

Impact factor: 1.862

47. Mortezaei A, Keller EX, Poyet C, **Hermanns T**, Saba K, Randazzo M, Fankhauser CD, Wild PJ, Moch H, Sulser T, Eberli D (2016)

Clinical impact of prostate biopsy undergrading in an academic and community setting.

World J Urol. 34(10):1481-90

Impact factor: 4.226

48. Templeton AJ, Knox JJ, Lin X, Simantov R, Xie W, Mitchell N, Broom R, Fay AP, Rini B, Donskov F, Bjarnason GA, Smoragiewicz M, Kollmannsberger C, Kanesvaran R, Alimohamed N, **Hermanns T**, Wells C, Amir E, Choueiri TK, Heng DY (2016)
Change in neutrophil to lymphocyte ratio in response to targeted therapy for metastatic renal cell carcinoma as a prognosticator and biomarker of efficacy.
Eur Urol. 70(2):358-64.
Impact factor: 20.096

49. Fankhauser CD, Bode PK, **Hermanns T**, Sander S, Sulser T, Altevogt P, Moch H, Tischler V (2016)
L1-CAM is commonly expressed in testicular germ cell tumors.
J Clin Pathol. 69(5):460-2.
Impact factor: 3.411

50. Poyet C, Wettstein MS, Lundon DJ, Bhindi B, Kulkarni GS, Saba K, Sulser T, Vickers AJ, **Hermanns T** (2016)
External evaluation of a novel prostate cancer risk calculator (ProstateCheck) based on data of the Swiss arm of the ERSPC.
J Urol. 196(5): 1402-7
Impact factor: 7.450

51. Kranzbühler B, Gross O, Fankhauser CD, Wettstein MS, Grossmann NC, Hefermehl LJ, Zimmermann M, Müller A, Eberli D, Sulser T, Poyet C, **Hermanns T** (2016)
Prostate volume reduction following pure transurethral bipolar plasma vaporization and conventional transurethral resection of the prostate: a prospective investigation using transrectal 3D ultrasound volumetry.
World J Urol. 35(3):429-435
Impact factor: 4.226

52. Wettstein MS, Saba K, Umbehr MH, Fankhauser CD, Adank JP, Hofmann M, Murtola T, Sulser T, **Hermanns T**, Wild PJ, Poyet C (2017)
Prognostic role of preoperative serum lipid levels in patients undergoing radical prostatectomy for clinically localized prostate cancer.
Prostate. 77(5):549-556
Impact factor: 4.104

53. Olkhov-Mitsel E, Savio AJ, Kron KJ, Pethe VV, **Hermanns T**, Fleshner NE, van Rhijn B, van der Kwast TH, Zlotta AR, Bapat B (2017)
Epigenome-wide DNA methylation profiling identifies differential methylation biomarkers in high grade bladder cancer.
Transl Oncol. 10(2):168-177
Impact factor: 4.243

54. Corro C, Hejhal T, Poyet C, Sulser T, **Hermanns T**, Winder T, Prager G, Wild PJ, Frew I, Moch H, Rechsteiner M (2017)
Detecting circulating tumor DNA in renal cancer: An open challenge.
Exp Mol Pathol. 102(2):255-261
Impact factor: 3.362
55. Zong Q, Guo T, Rechsteiner M, Rüschoff JH, Rupp N, Fankhauser C, Saba K, Mortezaei A, Poyet C, **Hermanns T**, Zhu Y, Moch H, Aebersold R, Wild PJ (2017)
A comprehensive collection of tissue microarray images and clinical outcome data of prostate cancer patients.
Sci Data. 4:170014
Impact factor: 6.444
56. Kulkarni GS, **Hermanns T***, Wei Y, Bhindi B, Satkunasivam R, Athanasopoulos P, Bostrom PJ, Kuk C, Li K, Templeton AJ, Sridhar SS, van der Kwast TH, Chung P, Bristow RG, Milosevic M, Warde P, Fleshner NE, Jewett MAS, Bashir S, Zlotta AR (2017)
Propensity Score Analysis of Radical Cystectomy Versus Bladder-Sparing Trimodal Therapy in the Setting of a Multidisciplinary Bladder Cancer Clinic.
J Clin Oncol. 35(20):2299-2305
Impact factor: 44.544
57. Mortezaei A, Salemi S, Rupp N, Rueschoff JH, **Hermanns T**, Poyet C, Randazzo M, Simon HU, Moch H, Sulser T, Wild PJ, Eberli D (2017)
Negative LC3b immunoreactivity in cancer cells is an independent prognostic predictor of prostate cancer specific death.
Oncotarget. 8(19):31765-31774
Impact factor: 5.168
58. Bezan A, Posch F, Ploner F, Bauernhofer T, Pichler M, Szkandera J, Hutterer GC, Pummer K, Gary T, Samonigg H, Beyrer J, Winder T, **Hermanns T**, Fankhauser CD, Gerger A, Stotz M (2017)
Risk stratification for venous thromboembolism in patients with testicular germ cell tumors.
PloS one. 12(4):e0176283
Impact factor: 3,240
59. Bhindi B, Fleshner NE, Finelli A, Hamilton RJ, **Hermanns T**, Toi A, Poyet C, Zlotta AR, Jiang H, Evans A, van der Kwast T, Li K, Kulkarni GS (2017)
Creation and internal validation of a biopsy avoidance prediction tool to aid in the choice of diagnostic approach in patients with prostate cancer suspicion.
Urol Oncol – Semin Ori. 35(10):604.e17-604.e24
Impact factor: 3.498
60. Mannil M, von Spiczak J, **Hermanns T**, Alkadhi H, Fankhauser CD (2017)
Prediction of successful shock wave lithotripsy with CT: a phantom study using texture analysis.

Abdom Radiol (NY). 43(6):1432-1438

Impact factor: 3.039

61. Fankhauser CD, Sander S, Roth L, Beyer J, **Hermanns T** (2018)
Improved survival in metastatic germ-cell cancer.
Ann Oncol. 29(2):347-351
Impact factor: 32.976
62. Erichsen L, Ghanjati F, Beermann A, Poyet C, **Hermanns T**, Schulz WA, Seifert HH, Wild PJ, Buser L, Kröning A, Braunstein S, Anlauf M, Jankowiak S, Hassan M, Bendhack ML, Bravo MA, Santourlidis S (2018)
Aberrant methylated key genes of methyl group metabolism within molecular etiology of urothelial carcinogenesis.
Sci Rep. 22;8(1):3477
Impact factor: 4.379
63. Mortezaei A, Märzendorfer O, Donati OF, Rizzi G, Rupp NJ, Wettstein MS, Gross O, Sulser T, **Hermanns T**, Eberli D (2018)
Diagnostic accuracy of mpMRI and fusion-guided targeted biopsy evaluated by transperineal template saturation prostate biopsy for the detection and characterization of prostate cancer.
J Urol. 200(2):309-318
Impact factor: 7.450
64. Fankhauser CD, Sander S, Roth L, Gross O, Eberli D, Sulser T, Seifert B, Beyer J, **Hermanns T**. (2018)
Systemic inflammatory markers have independent prognostic value in patients with metastatic testicular germ cell tumours undergoing first-line chemotherapy.
Br J Cancer. 118(6):825-830
Impact factor: 7.640
65. Fankhauser CD, Schöffler PJ, Gillessen S, Omlin A, Rupp NJ, Rueschoff JH, **Hermanns T**, Poyet C, Sulser T, Moch H, Wild PJ (2017)
Comprehensive immunohistochemical analysis of PD-L1 shows scarce expression in castration-resistant prostate cancer.
Oncotarget. 9(12):10284-10293
Impact factor: 5.168
66. Mannil M, von Spiczak J, **Hermanns T**, Poyet C, Alkadhi H, Fankhauser CD (2018)
Three-Dimensional texture analysis with machine learning provides incremental predictive information for successful shock wave lithotripsy in patients with kidney stones.
J Urol. 200(4):829-836
Impact factor: 7.450
67. Fankhauser CD, Mohebbi N, Grogg J, Holenstein A, Zhong Q, **Hermanns T**, Sulser T, Steurer J, Poyet C (2018)
Prevalence of hypertension and diabetes after exposure to extracorporeal shock-wave lithotripsy in patients with renal calculi: a retrospective non-randomized data analysis.
Int Urol Nephrol. 50(7):1227-1233

Impact factor: 2.370

68. **Hermanns T**, Grossmann NC, Wettstein MS, Keller EX, Fankhauser CD, Gross O, Kranzbühler B, Lüscher M, Meier AH, Sulser T, Poyet C (2019)
Is loss of power output due to laser fiber degradation still an issue during prostate vaporization using the 180 W GreenLight XPS laser?
World J Urol. 37(1):181-187

Impact factor: 4.226

69. Fankhauser CD, **Hermanns T**, Lieger L, Diethelm O, Umbehre M, Luginbühl T, Sulser T, Müntener M, Poyet C (2018)
Extracorporeal shock wave lithotripsy versus flexible ureterorenoscopy in the treatment of untreated renal calculi.
Clin Kidney J. 11(3):364-369

Impact factor: 4,452

70. Arvaniti E, Fricker KS, Moret M, Rupp N, **Hermanns T**, Fankhauser C, Wey N, Wild PJ, Rüschoff JH, Claassen M (2018)
Automated Gleason grading of prostate cancer tissue microarrays via deep learning.
Sci Rep. 8(1):12054

Impact factor: 4.379

71. Leão R, Lee D, Figueiredo A, **Hermanns T**, Wild P, Komosa M, Lau I, Mistry M, Nunes NM, Price AJ, Zhang C, Lipman T, Poyet C, Valtcheva N, Oehl K, Coelho H, Sayyid R, Gomes AM, Prado E Castro L, Sweet J, Vinagre J, Apolónio J, Stephens D, Faleiro I, Fadaak K, Richard PO, Kulkarni G, Zlotta AR, Hamilton RJ, Castelo-Branco P, Tabori U (2019)
Combined genetic and epigenetic alterations of the TERT promoter affect clinical and biological behaviour of bladder cancer.
Int J Cancer. 144(7):1676-1684

Impact factor: 7.396

72. Lee DD, Leão R, Komosa M, Gallo M, Zhang CH, Lipman T, Remke M, Heidari A, Nunes NM, Apolónio JD, Price AJ, De Mello RA, Dias JS, Huntsman D, **Hermanns T**, Wild PJ, Vanner R, Zadeh G, Karamchandani J, Das S, Taylor MD, Hawkins CE, Wasserman JD, Figueiredo A, Hamilton RJ, Minden MD, Wani K, Diplas B, Yan H, Aldape K, Akbari MR, Danesh A, Pugh TJ, Dirks PB, Castelo-Branco P, Tabori U (2019)
DNA hypermethylation within TERT promoter upregulates TERT expression in cancer.
J Clin Invest. 129(4):1801

Impact factor: 14.808

73. Keller EX, Bachofner J, Britschgi AJ, Saba K, Mortezaei A, Kaufmann B, Fankhauser CD, Wild P, Sulser T, **Hermanns T**, Eberli D, Poyet C (2018)
Prognostic value of unifocal and multifocal positive surgical margins in a large series of robot-assisted radical prostatectomy for prostate cancer.
World J Urol. 37(9):1837-44

Impact factor: 4.226

74. Tan WS, Ahmad A, Feber A, Mostafid H, Cresswell J, Fankhauser CD, Waisbrod S, **Hermanns T**, Sasieni P, Kelly JD; DETECT I trial collaborators. (2019)

Development and validation of a haematuria cancer risk score to identify patients at risk of harbouring cancer.

J Intern Med. 285(4):436-445

Impact factor: 8.989

75. **Hermanns T**, Gross O, Fankhauser CD, Wettstein MS, Grossmann NC, Keller EX, Eberli D, Sulser T, Poyet C, Kranzbühler B (2019)
Pure bipolar plasma vaporization of the prostate: 3-year results combining clinical mid-term outcome and 3D ultrasound volumetry data.
J Endourol. 33(2):107-112
Impact factor: 2.942
76. Bihl S, Ohashi R, Moore A, Rüschoff J, Beisel C, **Hermanns T**, Mischo A, Corro C, Beyer J, Beerenwinkel J, Moch H, Schraml P (2019)
Expression and mutation patterns of PBRM1, BAP1 and SETD2 mirror specific evolutionary subtypes in clear cell Renal Cell Carcinoma.
Neoplasia. 21(2):247-256.
Impact factor: 5.715
77. Fankhauser CD, Gerke TA, Roth L, Sander S, Grossmann NC, Kranzbühler B, Eberli D, Sulser T, Beyer J, **Hermanns T** (2019)
Pre-orchietomy tumor marker levels should not be used for International Germ Cell Consensus Classification (IGCCCG) risk group assignment.
J Cancer Res Clin Oncol. 145(3):781-85
Impact factor: 4.553
78. Schraml P, Athellogou M, **Hermanns T**, Huss R, Moch H (2019)
Specific immune cell and lymphatic vessel signatures identified by image analysis in renal cancer.
Mod Pathol. 32(7):1042-52
Impact factor: 7.842
79. Dieckmann KP, Radtke A, Geczi L, Matthies C, Anheuser P, Eckardt U, Sommer J, Zengerling F, Trenti E, Pichler R, Belz H, Zastrow S, Winter A, Melchior S, Hammel J, Kranz J, Bolten M, Kregge S, Haben B, Loidl W, Ruf CG, Heinzelbecker J, Heidenreich A, Cremers JF, Oing C, **Hermanns T**, Fankhauser CD, Gillessen S, Reichegger H, Cathomas R, Pichler M, Hentrich M, Eredics K, Lorch A, Wülfing C, Peine S, Wosniok W, Bokemeyer C, Belge G (2019)
Serum Levels of MicroRNA-371a-3p (M371 Test) as a New Biomarker of Testicular Germ Cell Tumors: Results of a Prospective Multicentric Study.
J Clin Oncol. 37(16):1412-23
Impact factor: 44.544
80. Wettstein MS, Rooprai JK, Pazhepurackel C, Wallis CJD, Klaassen Z, Uleryk EM, **Hermanns T**, Fleshner NE, Zlotta AR, Kulkarni GS (2019)
Systematic review and meta-analysis on trimodal therapy versus radical cystectomy for muscle-invasive bladder cancer: Does the current quality of evidence justify definitive conclusions?
PLoS One. 29;14(4)
Impact factor: 3.240

81. Wettstein MS, Pazhepurackel C, Neumann AS, Woon DTS, Herrera-Caceres JO, Kozomara M, Poyet C, Sulser T, Kulkarni GS, **Hermanns T** (2019)
Photoselective vaporization of the prostate: study outcomes as a function of risk of bias, conflicts of interest and industrial sponsorship
World J Urol. 38(3):741-746
Impact factor: 4.226
82. Shao W, Guo T, Toussaint NC, Xue P, Wagner U, Li L, Champi K, Zhu Y, Wu J, Buljan M, Sun R, Rutishauser D, **Hermanns T**, Fankhauser CD, Poyet C, Ljubicic J, Rupp N, Rüschoff JH, Zhong Q, Beyer A, Ji J, Collins BC, Liu Y, Rättsch G, Wild PJ, Aebersold R. (2019)
Comparative analysis of mRNA and protein degradation in prostate tissues indicates high stability of proteins
Nat Commun. 10(1):2524
Impact factor: 14.919
83. Kranzbühler B, Salemi S, Umbricht CA, Deberle LM, Müller C, Burger IA, **Hermanns T**, Sulser T, Eberli D (2019)
Concentration-dependent effects of dutasteride on prostate-specific membrane antigen (PSMA) expression and uptake of 177 Lu-PSMA-617 in LNCaP cells
Prostate. 79(12):1450-1456
Impact factor: 4.104
84. Hench IB, Cathomas R, Costa L, Fischer N, Gillessen S, Hench J, **Hermanns T**, Kremer E, Mingrone W, Mestre RP, Püschel H, Rothermundt C, Ruiz C, Tolnay M, Burg PV, Bubendorf L, Vlajnic T, Sakk SGFCCR. (2019)
Analysis of AR/ARV7 Expression in Isolated Circulating Tumor Cells of Patients with Metastatic Castration-Resistant Prostate Cancer (SAKK 08/14 IMPROVE Trial)
Cancers (Basel). 11(8):1099
Impact factor: 6.639
85. Fankhauser CD, Roth L, Grossmann NC, Kranzbühler B, Eberli D, Sulser T, Moch H, Bode PK, Beyer J, **Hermanns T**. (2019)
CXCL12 expression is an adverse predictor for disease recurrence in patients with metastatic non-seminomatous testicular germ cell tumors
BMC Cancer 14;19(1):802
Impact factor: 4.430
86. Ferraro DA, Muehlematter UJ, Garcia Schüler HI, Rupp NJ, Huellner M, Messerli M, Rüschoff JH, Ter Voert EEGW, **Hermanns T**, Burger IA (2019)
68 Ga-PSMA-11 PET has the potential to improve patient selection for extended pelvic lymph node dissection in intermediate to high-risk prostate cancer
Eur J Nucl Med Mol Imaging. 47(1):147-159
Impact factor: 9.236
87. Schmid FA, Wettstein MS, Kessler TM, **Hermanns T**, Boss A, Hötter AM, Eberli D (2019)
Contrast media kinetics in multiparametric magnetic resonance imaging before radical prostatectomy predicts the probability of postoperative incontinence
World J Urol. 38(7):1741-48
Impact factor: 4.226

88. Grogg JB, Schneider K, Bode PK, Wettstein MS, Kranzbühler B, Eberli D, Sulser T, Beyer J, **Hermanns T**, Fankhauser CD (2019)
A Systematic Review of Treatment Outcomes in Localised and Metastatic Spermatocytic Tumors of the Testis
J Cancer Res Clin Oncol. 145(12):3037-45
Impact factor: 4.553
89. Lebentrau S, Wolff I, Hempel MC, Haccius M, Kluth LA, Pycha A, Brookman-May S, Schneider TR, **Hermanns T**, Distler FA, Boegemann M, Kübler H, Shariat SF, Burger M, May M (2019)
Knowledge of German-speaking urologists regarding the association between penile cancer and human papilloma virus: results of a survey of the European PROspective Penile Cancer Study (E-PROPS)
Aktuelle Urol doi: 10.1055
Impact factor: 0.658
90. Tran B, Ruiz-Morales JM, Gonzalez-Billalabeitia E, Patrikidou A, Amir E, Seidel C, Bokemeyer C, Fankhauser C, **Hermanns T**, Rumyantsev A, Tryakin A, Brito M, Fléchon A, Kwan EM, Cheng T, Castellano D, Garcia Del Muro X, Hamid AA, Ottaviano M, Palmieri G, Kitson R, Reid A, Heng DY, Bedard PL (2020)
Large retroperitoneal lymphadenopathy and increased risk of venous thromboembolism in patients receiving first-line chemotherapy for metastatic germ cell tumors: A study by the global germ cell cancer group (G3)
Cancer Med. 9(1):116-24
Impact factor: 4.452
91. Ferraro DA, Garcia Schüler HI, Muehlematter UJ, Eberli D, Müller J, Müller A, Gablinger R, Kranzbühler H, Omlin A, Kaufmann PA, **Hermanns T***, Burger IA (2020)
Impact of 68 Ga-PSMA-11 PET staging on clinical decision-making in patients with intermediate or high-risk prostate cancer
Eur J Nucl Med Mol Imaging. 47(3):652-664
Impact factor: 9.236
92. Fankhauser CD, Grogg JB, Hayoz S, Wettstein MS, Dieckmann KP, Sulser T, Bode PK, Clarke NW, Beyer J, **Hermanns T** (2020)
Risk Factors and Treatment Outcomes of 1,375 Patients with Testicular Leydig Cell Tumors: Analysis of Published Case Series Data
J Urol. 203(5):949-56.
Impact factor: 7.450
93. Grogg J, Schneider K, Bode PK, Kranzbühler B, Eberli D, Sulser T, Lorch A, Beyer J, **Hermanns T**, Fankhauser CD
Sertoli Cell Tumors of the Testes: Systematic Literature Review and Meta-Analysis of Outcomes in 435 Patients
Oncologist 25(7):585-59
Impact factor: 5.025

94. **Hermanns T**, Savio AJ, Olkhov-Mitsel E, Mari A, Wettstein MS, Saba K, Bhindi B, Kuk C, Poyet C, Wild PJ, Noon A, Bashir S, Juvet T, Rendon RA, Waltregny D, van der Kwast T, Finelli A, Kulkarni GS, Fleshner NE, Lo K, Bapat B, Zlotta AR (2020)
A noninvasive urine-based methylation biomarker panel to detect bladder cancer and discriminate cancer grade
Urol Oncol Semin Ori 38(6):603.e1-.e7
Impact factor: 3.498
95. Erichsen L, Seifert HH, Schulz WA, Hoffmann MJ, Niegisch G, Araújo-Bravo MJ, Bendhack ML, Poyet C, **Hermanns T**, Beermann A, Hassan M, Theis L, Mahmood W, Santourlidis S (2020)
Basic Hallmarks of Urothelial Cancer Unleashed in Primary Uroepithelium by Interference with the Epigenetic Master Regulator ODC1
Sci Rep. 10(1):3808
Impact factor: 4.379
96. Wettstein MS, Naimark D, **Hermanns T**, Herrera-Caceres JO, Ahmad A, Jewett MAS, Kulkarni G (2020)
Required efficacy for novel therapies in BCG-unresponsive non-muscle invasive bladder cancer: Do current recommendations really reflect clinically meaningful outcomes?
Cancer Med. 9(10):3287-96
Impact factor: 4.452
97. Fankhauser CD, Waisbrod S, Fierz C, Becker AS, Kranzbühler B, Eberli D, Sulser T, Mostafid H, **Hermanns T**. (2020)
Diagnostic accuracy of ultrasonography, computed tomography, cystoscopy and cytology to detect urinary tract malignancies in patients with asymptomatic hematuria
World J Urol. 39(1):97-103.
Impact factor: 4.226
98. Seidel C, Daugaard G, Nestler T, Tryakin A, Fedyanin M, Fankhauser C, **Hermanns T**, Aparicio J, Heinzlbecker J, Paffenholz P, Heidenreich A, De Giorgi U, Cathomas R, Lorch A, Fingerhut A, Gayer F, Bremmer F, Giannatempo P, Necchi A, Aurilio G, Casadei C, Tran B, Dieckmann KP, Brito M, Ruf C, Oing C, Bokemeyer C (2020)
Human chorionic gonadotropin-positive seminoma patients: A registry compiled by the global germ cell tumor collaborative group (G3)
Eur J Cancer. 132:127-135
Impact factor: 9.162
99. Bieri U, Hübel K, Seeger H, Kulkarni GS, Sulser T, **Hermanns T**, Wettstein MS (2020)
Management of Active Surveillance-eligible Prostate Cancer during Pre-transplantation Work-up of Patients with Kidney Failure: A Simulation Study
Clin J Am Soc Nephrol. 15(6):822-829.
Impact factor: 8.237
100. Ferraro DA, Rüschoff JH, Muehlematter UJ, Kranzbühler B, Müller J, Messerli M, Husmann L, **Hermanns T**, Eberli D, Rupp NJ, Burger IA (2020)
Immunohistochemical PSMA expression patterns of primary prostate cancer tissue are associated with the detection rate of biochemical recurrence with 68 Ga-PSMA-11-PET Theranostics. 10(14):6082-6094

Impact factor: 11.556

101. Wyvekens N, Valtcheva N, Mischo A, Helmchen B, **Hermanns T**, Choschzick M, Hötker AM, Rauch A, Mühleisen B, Akhoundova D, Weber A, Moch H, Rupp NJ (2020)
Novel morphological and genetic features of fumarate hydratase deficient renal cell carcinoma in HLRCC syndrome patients with a tailored therapeutic approach
Genes Chromosomes Cancer. 2020 Nov;59(11):611-619
Impact factor: 5.006
102. Gallo A, Fankhauser C, **Hermanns T**, Beyer J, Christiansen A, Moch H, Bode PK (2020)
HNF1 β is a sensitive and specific novel marker for yolk sac tumor: a tissue microarray analysis of 601 testicular germ cell tumors
Mod Pathol. 33(11):2354-2360
Impact factor: 7.842
103. Fankhauser CD, Penney KL, Gonzalez-Feliciano AG, Clarke NW, **Hermanns T**, Stopsack KH, Fiorentino M, Loda M, Mahal B, Gerke TA, Preston MA, Mucci LA (2020)
Inferior Cancer Survival for Men with Localized High-grade Prostate Cancer but Low Prostate-specific Antigen
Eur Urol. 78(4):637-639.
Impact factor: 20.096
104. Fankhauser CD, Roth L, Kranzbühler B, Eberli D, Bode P, Moch H, Oliveira P, Ramani V, Beyer J, **Hermanns T** (2020)
The Role of Frozen Section Examination During Inguinal Exploration in Men with Inconclusive Testicular Tumors: A Systematic Review and Meta-analysis
Eur Urol Focus. S2405-4569(20)30185-1
Impact factor: 5.996
105. Grogg JB, Schneider K, Bode PK, Kranzbühler B, Eberli D, Sulser T, Beyer J, Lorch A, **Hermanns T**, Fankhauser CD (2020)
Risk Factors and Treatment Outcomes of 239 Patients with Testicular Granulosa Cell Tumors: A Systematic Review of Published Case Series Data
J Cancer Res Clin Oncol. 146(11):2829-2841
Impact factor: 3.282
106. Fankhauser CD, Wettstein MS, Reinhardt M, Gessendorfer A, Mostafid H, **Hermanns T**. (2020)
Indications and Complications of Androgen Deprivation Therapy
Semin Oncol Nurs. 36(4):151042
Impact factor: 2.315
107. Fankhauser CD, Tran B, Pedregal M, Ruiz-Morales JM, Gonzalez-Billalabeitia E, Patrikidou A, Amir E, Seidel C, Bokemeyer C, **Hermanns T**, Romyantsev A, Tryakin A, Brito M, Fléchon A, Kwan EM, Cheng T, Castellano D, Del Muro XG, Hamid AA, Ottaviano M, Palmieri G, Kitson R, Reid A, Heng DY, Bedard PL, Sweeney CJ, Connors JM. (2020)

A Risk-benefit Analysis of Prophylactic Anticoagulation for Patients with Metastatic Germ Cell Tumours Undergoing First-line Chemotherapy
Eur Urol Focus. S2405-4569(20)30280-7

Impact factor: 5.996

108. Ferraro DA, Lehner F, Becker AS, Kranzbühler B, Kudura K, Mebert I, Messerli M, **Hermanns T**, Eberli D, Burger IA (2021)
Improved oncological outcome after radical prostatectomy in patients staged with 68 Ga-PSMA-11 PET: a single-center retrospective cohort comparison
Eur J Nucl Med Mol Imaging. 48(4):1219-28
Impact factor: 9.236
109. Charmpi K, Guo T, Zhong Q, Wagner U, Sun R, Toussaint NC, Fritz CE, Yuan C, Chen H, Rupp NJ, Christiansen A, Rutishauser D, Rüschoff JH, Fankhauser C, Saba K, Poyet C, **Hermanns T**, Oehl K, Moore AL, Beisel C, Calzone L, Martignetti L, Zhang Q, Zhu Y, Martínez MR, Manica M, Haffner MC, Aebersold R, Wild PJ, Beyer A. (2020)
Convergent network effects along the axis of gene expression during prostate cancer progression
Genome Biol. 2020 Dec 14;21(1):302
Impact factor: 13.583
110. Kliesch S, Schmidt S, Wilborn D, Aigner C, Albrecht W, Bedke J, Beintker M, Beyersdorff D, Bokemeyer C, Busch J, Classen J, de Wit M, Dieckmann KP, Diemer T, Dieing A, Gockel M, Göckel-Beining B, Hakenberg OW, Heidenreich A, Heinzlbecker J, Herkommer K, **Hermanns T**, Kaufmann S, Kornmann M, Kotzerke J, Krege S, Kristiansen G, Lorch A, Müller AC, Oechsle K, Ohloff T, Oing C, Otto U, Pfister D, Pichler R, Recken H, Rick O, Rudolph Y, Ruf C, Schirren J, Schmelz H, Schmidberger H, Schrader M, Schweyer S, Seeling S, Souchon R, Winter C, Wittekind C, Zengerling F, Zermann DH, Zillmann R, Albers P (2021)
Management of Germ Cell Tumours of the Testis in Adult Patients. German Clinical Practice Guideline Part I: Epidemiology, Classification, Diagnosis, Prognosis, Fertility Preservation, and Treatment Recommendations for Localized Stages
Urol Int. 105(3-4):169-80
Impact factor: 2.089
111. Kliesch S, Schmidt S, Wilborn D, Aigner C, Albrecht W, Bedke J, Beintker M, Beyersdorff D, Bokemeyer C, Busch J, Classen J, de Wit M, Dieckmann KP, Diemer T, Dieing A, Gockel M, Göckel-Beining B, Hakenberg OW, Heidenreich A, Heinzlbecker J, Herkommer K, **Hermanns T**, Kaufmann S, Kornmann M, Kotzerke J, Krege S, Kristiansen G, Lorch A, Müller AC, Oechsle K, Ohloff T, Oing C, Otto U, Pfister D, Pichler R, Recken H, Rick O, Rudolph Y, Ruf C, Schirren J, Schmelz H, Schmidberger H, Schrader M, Schweyer S, Seeling S, Souchon R, Winter C, Wittekind C, Zengerling F, Zermann DH, Zillmann R, Albers P (2021)
Management of Germ Cell Tumours of the Testes in Adult Patients: German Clinical Practice Guideline, PART II - Recommendations for the Treatment of Advanced, Recurrent, and Refractory Disease and Extragonadal and Sex Cord/Stromal Tumours and for the Management of Follow-Up, Toxicity, Quality of Life, Palliative Care, and Supportive Therapy
Urol Int. 105(3-4):181-191
Impact factor: 2.089

112. Grogg JB, Fronzaroli JN, Oliveira P, Bode PK, Lorch A, Issa A, Beyer J, Eberli D, Sangar V, **Hermanns T**, Clarke NW, Fankhauser CD (2021)
Clinicopathological characteristics and outcomes in men with mesothelioma of the tunica vaginalis testis: analysis of published case-series data
J Cancer Res Clin Oncol. 2021 Sep;147(9):2671-2679
Impact factor: 4.553
113. Wettstein MS, David LA, Pazhepurackel C, Qureshi AA, Zisman A, Nesbitt M, Saba K, Herrera-Caceres JO, Fankhauser CD, Ahmad A, Hamilton RJ, Eberli D, Zlotta AR, Sulser T, Fleshner NE, Poyet C, Finelli A, **Hermanns T***, Kulkarni GS (2021)
Benefit of a more extended pelvic lymph node dissection among patients undergoing radical prostatectomy for localized prostate cancer: A causal mediation analysis
Prostate. 2021 Apr;81(5):286-294
Impact factor: 4.104
114. Seidel C, Daugaard G, Nestler T, Tryakin A, Fedyanin M, Fankhauser CD, **Hermanns T**, Aparicio J, Heinzlbecker J, Paffenholz P, Heidenreich A, De Giorgi U, Cathomas R, Lorch A, Fingerhut A, Gayer F, Bremmer F, Giannatempo P, Necchi A, Raggi D, Aurilio G, Casadei C, Hentrich M, Tran B, Dieckmann KP, Brito M, Ruf C, Mazzocca A, Vincenzi B, Stahl O, Bokemeyer C, Oing C (2021)
The prognostic significance of lactate dehydrogenase levels in seminoma patients with advanced disease: an analysis by the Global Germ Cell Tumor Collaborative Group (G3)
World J Urol. Epub ahead of print
Impact factor: 4.226
115. Waisbrod S, Natsos A, Wettstein MS, Saba K, **Hermanns T**, Fankhauser CD, Müller A. (2021)
Assessment of Diagnostic Yield of Cystoscopy and Computed Tomographic Urography for Urinary Tract Cancers in Patients Evaluated for Microhematuria: A Systematic Review and Meta-analysis
JAMA Netw Open. 4(5):e218409.
Impact factor: 8.483
116. Fankhauser CD, Weber D, Müntener M, Poyet C, Sulser T, **Hermanns T** (2021)
Effectiveness of Flexible Ureterorenoscopy Versus Extracorporeal Shock Wave Lithotripsy for Renal Calculi of 5-15 mm: Results of a Randomized Controlled Trial
Eur Urol Open Sci. 25:5-10
Impact factor: n/a
117. Saba K, Högger DC, Hötker AM, Rupp NJ, Sulser T, **Hermanns T**. (2021)
Dignity of Small Renal Masses: Implications for Diagnostics and Therapy
Praxis (Bern 1994). 110(10):565-570
Impact factor: n/a
118. Rüschoff JH, Ferraro DA, Muehlematter UJ, Laudicella R, Hermanns T, Rodewald AK, Moch H, Eberli D, Burger IA, Rupp NJ (2021)
What's behind 68Ga-PSMA-11 uptake in primary prostate cancer PET? Investigation of histopathological parameters and immunohistochemical PSMA expression patterns.
Eur J Nucl Med Mol Imaging. Epub ahead of print
Impact factor: 9.236

2. Editorials

119. Poyet C, **Hermanns T** (2016)
Prostate cancer risk calculators: still much work ahead.
BJU Int. 118(5):670-671
Impact factor: 5.588
120. **Hermanns T**, Poyet C (2017)
The next generation of prostate cancer risk calculators.
Eur Urol. 72(6):897-898
Impact factor: 20.096

3. Case reports

121. Zeh N, Wild PJ, Bode P, Moch H, Kristiansen G, Sulser T, **Hermanns T** (2013)
Retroperitoneal teratoma with somatic malignant transformation: A papillary renal cell carcinoma in a germ cell tumour metastasis following platinum-based chemotherapy.
BMC Urol. 13:9
Impact factor: 2.264
122. Poyet C, Grubhofer F, Zimmermann M, Sulser T, **Hermanns T** (2013)
Therapy-resistant nephrolithiasis following renal artery coil embolization.
BMC Urol. 13:29
Impact factor: 2.264
123. Fankhauser CD, **Hermanns T**, Hasse B, Rancic Z
Excessive wound fluid discharge during retroperitoneal negative pressure wound therapy
Ann Vasc Surg. 43:314.e1-314.e3
Impact factor: 1.466

4. Reviews

124. Seifert HH, **Hermanns T**, Sulser T (2008)
GreenLight laser vaporisation of the prostate for treatment of benign prostatic hyperplasia. Development and significance.
Urologe. 47(8): 964-8
Impact factor: 0.639
125. Fankhauser CD, Kranzbühler B, Poyet C, **Hermanns T**, Sulser T, Steurer J (2015)
Long-term adverse effects of extracorporeal shock-wave lithotripsy for nephro- and ureterolithiasis: a systematic review.

Urology. 85(5): 991-1006

Impact factor: 2.649

126. Kozomara M, **Hermanns T**, Poyet C (2016)

Male Urinary Incontinence – A Taboo Issue.

Praxis. 105(5): 269-77

Impact factor: n/a

127. Fankhauser CD, Poyet C, Kroeze SGC, Kranzbühler B, Schüler HIG, Guckenberger M, Kaufmann PA, **Hermanns T**, Burger IA. (2018)

Current and potential future role of PSMA-PET in patients with castration-resistant prostate cancer.

World J Urol. 37(3):457-467

Impact factor: 4.226

5. Book Chapter

128. **Hermanns T**, Sulser T

Interventional treatment: Prostate Laser.

Benign prostatic hyperplasia and lower urinary tract symptoms in man, Oxford Urology Library, editors: A. Bachmann & JJMCH de la Rosette, Oxford University Press 2012

129. **Hermanns T**, Kuk C, Zlotta AR

Prostate cancer: Clinical Presentation, Diagnosis and Staging.

Urological Oncology, editors: VH Nargund, D Raghavan, HM Sandler Springer Verlag, London 2015

6. Proceedings

130. **Hermanns T**, Sulser T, Fatzer M, Baumgartner MK, Rey JM, Sigrist MW, Seifert HH (2008)

Intra-operative power measurement of laser fibers during photoselective vaporization of the prostate using the 80W-KTP-Greenlight laser.

Proceedings of SPIE, Vol. 6842; Progress in Biomedical Optics and Imaging Vol. 9, No. 1; Photonic Therapeutics and Diagnostics IV, 684211

131. **Hermanns T**, Sulser T, Hefermehl LJ, Strebel DD, Michel MS, Müntener M, Meier AH, Seifert HH (2009)

Loss of Power Output and Laser Fibre Degradation during 120 Watt Lithium-Triborate HPS Laser Vaporisation of the Prostate.

Proceedings of SPIE, Vol. 7161; Progress in Biomedical Optics and Imaging Vol. 10, No. 1; Photonic Therapeutics and Diagnostics V, 71611-1

132. Gross O, Sulser T, Hefermehl LJ, Strebel DD, Largo R, Mortezaei A, Poyet C, Eberli D, Zimmerman M, Müller A, Michel MS, Müntener M, Seifert HH, **Hermanns T** (2011)
Ablative efficiency of lithium-triborate laser vaporisation and conventional transurethral resection of the prostate: A comparison using transrectal three-dimensional ultrasound volumetry.
Proceedings of SPIE, Vol. 7883; Progress in Biomedical Optics and Imaging Vol. 12, No. 1; Photonic Therapeutics and Diagnostics VII, 78831-1
133. Kranzbühler B, Gross O, Fankhauser CD, Hefermehl LJ, Poyet C, Largo R, Müntener M, Seifert HH, Zimmermann M, Sulser T, Müller A, **Hermanns T** (2012)
Tissue ablation after 120W greenlight laser vaporization and bipolar plasma vaporization of the prostate. A comparison using transrectal three-dimensional ultrasound volumetry.
Proceedings of SPIE, Vol. 8207; Progress in Biomedical Optics and Imaging Vol.; Photonic Therapeutics and Diagnostics VIII, 820783-1

7. Letters

134. Fankhauser CD, Grossmann NC, Beyer J, **Hermanns T**. (2018)
Re: Sophia C. Kamran, Thomas Seisen, Sarah C. Markt, et al. Contemporary Treatment Patterns and Outcomes for Clinical Stage IS Testicular Cancer. Eur Urol 2018;73:262-70.
Eur Urol. 73(4):e94-e95
Impact factor: 20.096